bioRxivCancer BiologyPreprint
CREBBP lysine acetyltransferase domain mutations create zombie enzymes that alter chromatin loading dynamics and prevent EP300 redundancy
H. Yang, W. Zhang, V. Ravanmehr, A. Mechaly, L. Regad, A. Haouz, R. Chen, J. Henderson, E. Rojas, A. Wilson, S. Parsons, L. Nastoupil, R. E. Davis, Q. Deng, F. Samaniego, F. Rodrigues-Lima, M. R. Green
Abstract
Epigenetic regulation of gene expression is fundamental to cell state transitions. A prominent example of this is the epigenetically-regulated generation of transitory cells states within the germinal center (GC) reaction that are required for humoral immunity. The deregulation of these processes through somatic mutations can give rise to B-cell lymphoma, thus studying these mutations can provide insight into fundamental mechanisms underlying epigenetic regulation of gene expression as well as GC B-cell and lymphoma biology. Here we show that classes of mutations in the CREBBP lysine acetyltransferase gene result in different structure, catalytic activity and function. We discover that CREBBP and its paralog EP300 are dynamically and reciprocally loaded onto chromatin during a signal-responsive cell state transitions within the GC. Mutation of CREBBP in GC-derived lymphoma interrupt signal-responsive CREBBP loading onto chromatin, while also inhibiting EP300 redundancy. These observations lead to a model in which CREBBP or EP300 loss of function through acetyltransferase domain mutations, which occur frequently in both hematopoietic and solid tumors, create a zombie enzyme that retards the function of the active paralog by binding limiting concentrations of transcription factor substrate and preventing signal-responsive enhancer activation.
- organism: mouse
- assay: ChIP-seq
- research focus: chromatin & epigenetic regulation
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma
P. Mondello, S. Tadros, … M. Green·bioRxiv·Jan 27, 2019
- Mutational synergy with CREBBP loss in lymphomagenesis identified through forward insertional mutagenesis in a new DLBCL mouse model
N. Sakakini, R. Straver, … B. J. P. Huntly·bioRxiv·Mar 25, 2024
- Essentiality of CREBBP in EP300 truncated B-cell lymphoma revealed by genome-wide CRISPR-Cas9 screen
M. Nie, B. Zhang, … Q. P. Hammarstrom·bioRxiv·Aug 28, 2019
- A Novel CREBBP/p300 Activator, YF2, Enhances Cytotoxic and Immune-Mediated Responses in B-Cell Lymphoma
Ted B. Piorczynski, Yuxuan Liu, … Jennifer Effie Amengual·bioRxiv·Mar 13, 2025
- Cooperative super-enhancer inactivation caused by heterozygous loss of CREBBP and KMT2D skews B cell fate decisions and yields T cell-depleted lymphomas
J. Li, C. R. Chin, … A. M. Melnick·bioRxiv·Feb 13, 2023
- B Cell Receptor Signaling Drives APOBEC3 Expression Via Direct Enhancer Regulation in Chronic Lymphocytic Leukemia B Cells